Aclarion, Inc. (ACONW) company profile
Close on Oct 30, 2026Market cap $5.62MP/E –Yield –
About Aclarion
Services-Medical Laboratories, SIC 8071
Aclarion, Inc. is a healthcare technology company that utilizes Magnetic Resonance Spectroscopy and proprietary biomarkers to enhance clinical treatments for back and neck pain. Its proprietary software transforms spectroscopy signal data into biomarkers to help determine whether an intervertebral disc is a source of chronic pain. The company primarily targets chronic discogenic low back pain by assisting spine surgeons in selecting optimal surgical interventions.
Operating within the medical technology sector, Aclarion focuses on the chronic low back and cervical spine pain markets. Its diagnostic software serves clinicians and surgical teams seeking objective, noninvasive evaluation of lumbar discs prior to operative intervention. As of the report date, the company maintains its principal executive offices in Broomfield, Colorado.
Summary of the business section of Aclarion's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Aclarion, Inc.
- Headquarters
- Broomfield, CO
- Address
- 8181 Arista Place, Ste 100 80021
- Phone
- (833) 275-2266
- Website
- aclarion.com
- Employees
- 11, Dec 31, 2025
- Industry
- Services-Medical Laboratories
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Haynie & Company, Salt Lake City, Utah
Stock & identifiers
- Ticker
- ACONW
- Other tickers
- ACON
- Exchange
- Nasdaq
- IPO date
- Apr 25, 2022
- Shares outstanding
- 3M, Aug 4, 2026
- Public float
- $4.39M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Stock splits
- 1-for-9047 reverse, Apr 9, 2025; 1-for-27 reverse, Mar 28, 2025; 1-for-335 reverse, Jan 30, 2025; 1-for-16 reverse, Jan 4, 2024
- SEC CIK
- 1635077
- CUSIP
- 655187110
- ISIN
- US6551871105
- FIGI
- BBG016Z2HS66
- LEI
- 529900MGK6H51761Z546
- EIN
- 47-3324725
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Brent Ness | Chief Executive Officer, Director | 111,534 |
| Jeffrey John Thramann | Executive Chairman, Director | 100,000 |
| Gregory A. Gould | CFO | 60,000 |
| Amanda Mae Sequira | Director | 25,857 |
| William Wesemann | Director | 23,713 |
| David K. Neal | Director | 30,002 |
| Ryan Bond | Director | 76,122 |
| Stephen Deitsch | Director | 20,000 |
| Scott Breidbart | Director | 25,664 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Option awards | Total | vs. prior year |
|---|---|---|---|---|---|
| Jeff Thramann Executive Director | $300.00K | $162.50K | – | $462.50K | +21% |
| Brent Ness Chief Executive Officer | $300.00K | $162.50K | – | $462.50K | +21% |
| Gregory Gould Chief Financial Officer(5) | $87.50K | $32.90K | $6.17K | $126.58K | – |
| Ryan Bond Chief Strategy Officer | $200.00K | $54.17K | – | $254.17K | +12% |
| John Lorbiecki Chief Financial Officer(6) | $170.48K | – | – | $170.48K | -40% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Apr 25, 2022
- Offer price
- $4.35
- Securities offered
- 2,165,000
- Gross proceeds
- $9.42M
- Exchange
- Nasdaq
- First trading day
- Apr 22, 2022
- First-day close
- $2.72-37.6%
- Lock-up ends (est.)
- Oct 19, 2022
“Per Unit Total Initial public offering price $ 4.350 $ 9,417,750 Underwriting discounts and commissions (1) $ .348 $ 753,420 Proceeds to Aclarion, Inc., before expenses $ 4.002 $ 8,664,330 __________________ (1) The underwriters will receive compensation in addition to the underwriting discounts and commissions.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of January 1, 2026, we had 11 total employees,”
Corporate history
Events identified from SEC filings